amgen glp 1 drug Amgen's AMG-133 shows potential in competing with GLP-1RA obesity therapies π The next trillion-dollar drug
Description
Gastroenterology (2007) 132(6):213157
GLP-1-based treatments mark a major advancement in managing obesity and type 2 diabetes, offering added benefits for heart and brain health
10.2147/DDDT.S81998 67 PatelF.AG.ChangK.VegaK
Consistent with the FAP-based approach, stimulation with PF-06882961 for 30 minutes triggered marked intracellular accumulation of GFP-GLP-1R, which was reversible following a 2-hour washout period
The cost of GLP-1 receptor agonists is about two to three times higher than SGLT-2 inhibitors
